**巴黎生物技术公司Aqemia完成3000万欧元A轮融资追加，加速药物发现进程**
总部位于法国巴黎的初创公司Aqemia，一家利用人工智能进行量子药物发现和设计的创新企业，近日宣布成功获得3000万欧元的A轮融资追加资金。这使得A轮全股权融资总额达到6000万欧元，彰显了投资者对其技术潜力和市场前景的强烈信心。本轮融资由知名投资机构Wendel Growth领投，法国风险投资公司Eurazeo、公共银行Bpifrance以及Elaia等现有投资者参与跟投。
Aqemia的核心技术在于其人工智能驱动的分子发现和设计平台，该平台能够显著加快新药物的研发进程。据公司介绍，通过利用先进的人工智能算法，Aqemia能够精准预测分子的属性，从而更高效地筛选出可能对抗各种疾病的潜在药物分子。
这笔新的资金注入将助力Aqemia进一步提升其人工智能技术的研发能力，扩大团队规模，并加速药物发现项目，以期在对抗全球健康挑战的战场上发挥更大的作用。Aqemia的创新模式不仅有可能重塑药物研发行业，还可能为未来的医疗解决方案开辟新的道路。
此次融资是Aqemia发展历程中的一个重要里程碑，它表明科技与医疗的结合正在全球范围内引起广泛关注，并吸引着资本的积极投入。随着人工智能在生物技术领域的应用日益广泛，Aqemia有望成为这一领域的领军企业，为全球的公共卫生事业做出贡献。
英语如下：
**News Title:** “AI-driven Pharmaceutical Startup Aqemia Secures €60 Million Funding to Accelerate Drug Discovery Revolution”
**Keywords:** Aqemia, Drug Discovery, Artificial Intelligence Funding
**News Content:**
**Paris-based biotech company Aqemia completes €30 million Series A extension to hasten drug discovery**
Aqemia, a pioneering Paris-based startup leveraging artificial intelligence for quantum drug discovery and design, has announced a successful €30 million Series A extension round. This brings the total equity funding for the Series A to €60 million, reflecting strong investor confidence in the company’s technological potential and market prospects. The round was led by prominent investment firm Wendel Growth, with participation from French venture capital company Eurazeo, public bank Bpifrance, and existing investor Elaia.
At the heart of Aqemia’s offering is its AI-powered molecular discovery and design platform, which significantly speeds up the new drug development process. The company claims that by leveraging advanced AI algorithms, it can accurately predict molecular properties, enabling a more efficient screening of potential drug molecules to combat various diseases.
The fresh injection of funds will enable Aqemia to enhance its AI technology R&D, expand its team, and accelerate drug discovery projects, positioning the company to play a larger role in addressing global health challenges. Aqemia’s innovative approach has the potential to reshape the pharmaceutical R&D industry and pave the way for novel medical solutions.
This funding round marks a significant milestone in Aqemia’s journey, signifying the growing global interest in the convergence of technology and healthcare, and the corresponding influx of capital. As AI’s application in the biotech sector widens, Aqemia is poised to emerge as a key player, contributing to global public health initiatives.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 1